BACKGROUND: Hypoglycaemic drugs that close the KATP channel have been tested in patients with permanent neonatal diabetes due to glucokinase mutations (PNDM-GCK). From the results obtained, it has been suggested that this treatment may be beneficial in patients carrying GCK mutations with mild kinetic defects. The aim of this study was to evaluate the kinetic analysis of glucokinase activity as a predictive factor for response to sulphonylureas in PNDM-GCK. METHODS: The clinical characteristics of two siblings with PNDM born to non-consanguineous parents are described. Mutation analysis of KCNJ11, INS and GCK genes was done by sequencing. A comprehensive functional characterisation of GCK mutation was undertaken. Glibenclamide treatment was assayed for 16 weeks in one child. Response to treatment was evaluated by means of fasting glycaemia, C-peptide and HbA1c levels. RESULTS: Compound heterozygous GCK mutations (p.Ile19Asn and p.Ser441Trp) were identified. Functional analysis of GCK(p.Ile19Asn) indicated that this mutant retained more than 70% of wild-type catalytic activity in vitro, with a slight increase of thermolability. This mutation did not impair the interaction with the glucokinase regulatory protein, and the enzymatic activity of the GCK(p.Ile19Asn) mutant is restored to wild-type levels in the presence of GCK allosteric activator LY2121260. However, glibenclamide treatment of the patient on a reduced dose of insulin did not reduce HbA1c levels, and C-peptide increased only very slightly. CONCLUSION: Hypoglycaemic drugs acting on the KATP channel might not be useful in the treatment of PNDM-GCK, even in patients carrying GCK mutations with mild kinetic defects.
BACKGROUND: Hypoglycaemic drugs that close the KATP channel have been tested in patients with permanent neonatal diabetes due to glucokinase mutations (PNDM-GCK). From the results obtained, it has been suggested that this treatment may be beneficial in patients carrying GCK mutations with mild kinetic defects. The aim of this study was to evaluate the kinetic analysis of glucokinase activity as a predictive factor for response to sulphonylureas in PNDM-GCK. METHODS: The clinical characteristics of two siblings with PNDM born to non-consanguineous parents are described. Mutation analysis of KCNJ11, INS and GCK genes was done by sequencing. A comprehensive functional characterisation of GCK mutation was undertaken. Glibenclamide treatment was assayed for 16 weeks in one child. Response to treatment was evaluated by means of fasting glycaemia, C-peptide and HbA1c levels. RESULTS: Compound heterozygous GCK mutations (p.Ile19Asn and p.Ser441Trp) were identified. Functional analysis of GCK(p.Ile19Asn) indicated that this mutant retained more than 70% of wild-type catalytic activity in vitro, with a slight increase of thermolability. This mutation did not impair the interaction with the glucokinase regulatory protein, and the enzymatic activity of the GCK(p.Ile19Asn) mutant is restored to wild-type levels in the presence of GCK allosteric activator LY2121260. However, glibenclamide treatment of the patient on a reduced dose of insulin did not reduce HbA1c levels, and C-peptide increased only very slightly. CONCLUSION: Hypoglycaemic drugs acting on the KATP channel might not be useful in the treatment of PNDM-GCK, even in patients carrying GCK mutations with mild kinetic defects.
Authors: Fabrizio Barbetti; Nadia Cobo-Vuilleumier; Carlo Dionisi-Vici; Sonia Toni; Paolo Ciampalini; Ornella Massa; Pablo Rodriguez-Bada; Carlo Colombo; Lorenzo Lenzi; María A Garcia-Gimeno; Francisco J Bermudez-Silva; Fernando Rodriguez de Fonseca; Patrizia Banin; Juan C Aledo; Elena Baixeras; Pascual Sanz; Antonio L Cuesta-Muñoz Journal: Mol Endocrinol Date: 2009-11-02
Authors: Maria Negahdar; Ingvild Aukrust; Janne Molnes; Marie H Solheim; Bente B Johansson; Jørn V Sagen; Knut Dahl-Jørgensen; Rohit N Kulkarni; Oddmund Søvik; Torgeir Flatmark; Pål R Njølstad; Lise Bjørkhaug Journal: Mol Cell Endocrinol Date: 2013-08-31 Impact factor: 4.102
Authors: Małgorzata Wajda-Cuszlag; Daniel Witkowski; Elżbieta Piontek; Marta Wysocka-Mincewicz; Maciej Borowiec; Wojciech Młynarski; Mieczysław Szalecki Journal: Pediatr Endocrinol Diabetes Metab Date: 2012
Authors: Itziar Estalella; Itxaso Rica; Guiomar Perez de Nanclares; Jose Ramon Bilbao; Jose Antonio Vazquez; Jose Ignacio San Pedro; Maria Angeles Busturia; Luis Castaño Journal: Clin Endocrinol (Oxf) Date: 2007-06-15 Impact factor: 3.478
Authors: Pål R Njølstad; Jørn V Sagen; Lise Bjørkhaug; Stella Odili; Naim Shehadeh; Doua Bakry; S Umit Sarici; Faruk Alpay; Janne Molnes; Anders Molven; Oddmund Søvik; Franz M Matschinsky Journal: Diabetes Date: 2003-11 Impact factor: 9.461
Authors: Henrik B T Christesen; Bendt B Jacobsen; Stella Odili; Carol Buettger; Antonio Cuesta-Munoz; Torben Hansen; Klaus Brusgaard; Ornella Massa; Mark A Magnuson; Chiyo Shiota; Franz M Matschinsky; Fabrizio Barbetti Journal: Diabetes Date: 2002-04 Impact factor: 9.461
Authors: Adriana Mangue Esquiaveto-Aun; Maricilda Palandi De Mello; Maria Fernanda Vanti Macedo Paulino; Walter José Minicucci; Gil Guerra-Júnior; Sofia Helena Valente De Lemos-Marini Journal: Diabetol Metab Syndr Date: 2015-11-18 Impact factor: 3.320